TrialNature cancer2023

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.

Claudia M Denkinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.